Voya Investment Management LLC grew its stake in shares of DURECT Corporation (NASDAQ:DRRX) by 22.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 82,826 shares of the specialty pharmaceutical company’s stock after purchasing an additional 15,394 shares during the quarter. Voya Investment Management LLC owned approximately 0.06% of DURECT Corporation worth $129,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of DRRX. Vanguard Group Inc. lifted its stake in DURECT Corporation by 3.3% in the second quarter. Vanguard Group Inc. now owns 5,368,184 shares of the specialty pharmaceutical company’s stock worth $8,374,000 after acquiring an additional 169,226 shares during the period. Northern Trust Corp lifted its stake in DURECT Corporation by 10.9% in the second quarter. Northern Trust Corp now owns 1,577,145 shares of the specialty pharmaceutical company’s stock worth $2,460,000 after acquiring an additional 154,640 shares during the period. Tocqueville Asset Management L.P. lifted its stake in DURECT Corporation by 48.4% in the second quarter. Tocqueville Asset Management L.P. now owns 1,200,000 shares of the specialty pharmaceutical company’s stock worth $1,872,000 after acquiring an additional 391,500 shares during the period. Bank of New York Mellon Corp lifted its stake in DURECT Corporation by 4.1% in the second quarter. Bank of New York Mellon Corp now owns 370,387 shares of the specialty pharmaceutical company’s stock worth $578,000 after acquiring an additional 14,553 shares during the period. Finally, State of Wisconsin Investment Board purchased a new stake in DURECT Corporation in the second quarter worth about $151,000. 46.13% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “DURECT Corporation (DRRX) Stake Increased by Voya Investment Management LLC” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/11/24/durect-corporation-drrx-stake-increased-by-voya-investment-management-llc.html.

Shares of DURECT Corporation (NASDAQ:DRRX) opened at $1.15 on Friday. DURECT Corporation has a one year low of $0.74 and a one year high of $2.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 1.67 and a quick ratio of 1.57.

DURECT Corporation (NASDAQ:DRRX) last released its quarterly earnings data on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.09. The company had revenue of $20.75 million during the quarter, compared to analyst estimates of $5.09 million. DURECT Corporation had a negative net margin of 62.57% and a negative return on equity of 419.65%. analysts expect that DURECT Corporation will post -0.14 EPS for the current fiscal year.

A number of analysts recently weighed in on DRRX shares. Laidlaw lowered their price objective on shares of DURECT Corporation from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, October 20th. ValuEngine lowered shares of DURECT Corporation from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 21st. Stifel Nicolaus lowered shares of DURECT Corporation from a “buy” rating to a “hold” rating in a research note on Friday, October 20th. Finally, HC Wainwright reaffirmed a “hold” rating on shares of DURECT Corporation in a research note on Thursday, November 2nd.

About DURECT Corporation

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Institutional Ownership by Quarter for DURECT Corporation (NASDAQ:DRRX)

Receive News & Stock Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related stocks with our FREE daily email newsletter.